<DOC>
	<DOCNO>NCT02963077</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability pharmacokinetics A4250 single multiple oral dos healthy subject . In addition , evaluate A4250 combination cholestyramine .</brief_summary>
	<brief_title>A Safety Pharmakokinetic Study A4250 Alone Combination With A3384</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<mesh_term>Alagille Syndrome</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<criteria>1 . Healthy male nonpregnant , nonlactating healthy female 2 . BMI 18 32 kg/m2 , outside range , consider clinically significant investigator 3 . Willing able communicate participate whole study 4 . Provided write informed consent 5 . Agreed use adequate method contraception 1 . Had participate clinical research study within previous 3 month 2 . Were study site employee , immediate family member study site sponsor employee 3 . Had previously enrol study 4 . History drug alcohol abuse past 2 year 5 . Regular alcohol consumption , male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = Â½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 6 . Current smoker smoke within last 12 month . A breath carbon monoxide ( CO ) reading great 10 ppm screen 7 . Females childbearing potential pregnant lactating ( female subject must negative urine pregnancy test admission ) 8 . Did suitable vein multiple venepunctures/cannulation assess investigator screen 9 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 10 . Positive drug abuse test result 11 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 12 . History cardiovascular , renal , hepatic , chronic respiratory GI disease judge investigator 13 . Serious adverse reaction serious hypersensitivity drug formulation excipients eg lactose contraindication cholestyramine/Questran 14 . Presence history clinically significant allergy require treatment per judgement investigator Hayfever allow unless active 15 . Donation loss great 400 mL blood within previous 3 month 16 . Were take , take , prescribed overthecounter drug ( 4 g per day paracetamol , hormone replacement therapy [ HRT ] hormonal contraception ) herbal remedy 14 day IMP administration unless consider interfered objective study , agree PI sponsor 's medical monitor case case basis 17 . Failed satisfy investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>